Back of the napkin Covid test valuation.
Assume:
Price per test, US$10.00
Manufacturing cost, $3.33
Distributor margin, $3.33
Gross Profit per unit, $3.34
Operon Sales
20,000,000 @ GP $3.34
$66,800,000
Anteo (direct) Sales
12,000,000 @ (say) GP $6.34
$76,080,000
Total Gross Profit
$142,880,000
P/E ratio of 20x
COVID-19 Business Value
$2,857,600,000
Shares on issue
1,900,000,000
Value per Share.
$1.50 Risk adjusted
@ 50%. $0.75
Thoughts?
Ann: EuGeni Test Strip Manufacturing Strategy, page-49
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.001(5.26%) |
Mkt cap ! $49.37M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.9¢ | $15.05K | 758.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2299968 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 209963 | 3 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| ADO (ASX) Chart |